The National Health Surveillance Agency (Anvisa) issued a warning regarding the circulation of counterfeit batches of medicines in Brazil. The statement warns mainly about the medicine Tysabri (natalizumab), for the treatment of multiple sclerosis, and Ozempic (semaglutide), for adults with type 2 diabetes.
Biogen Brasil, which holds the Tysabri registration, stated that batch FF00336 was produced institutionally, not for commercial purposes. Therefore, the product has different characteristics from the original medicine, such as: difference in the color of the box, the typography of the font and the absence of Braille adaptation.
The pharmaceutical company Nova Nordisk, responsible for Ozenpick, stated that it does not recognize the medicine in circulation. Therefore, it is a complete falsification, even presenting a different concentration of the original substance.
